GIKLY News and Press, Grifols SA Barcelona ADR From 02/09/22

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...

Meletios Verras/iStock via Getty Images Grifols ([[GIKLY]]) says that the novel mechanism of action of subsidiary GigaGen's anti-CTLA-4 drug candidate, GIGA-564, for cancer indications leads to superior anti-tumor activity and lower toxicity in a mouse model. GigaGen says that GIGA-564 differ...

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...

The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow

Grifols ([[GIKLY]]) announces that it has begun commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin for hepatitis B postexposure prophylaxis.The new formulation, which was approved by the U.S. FDA in December 2020, uses a unique caprylate chromatography process, w...

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B - The new formulation delivers anti-hepatitis B virus antibodies using a unique and sophisticated caprylate chromatography process - Grifols ...

Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...

Grifols installs first-ever DG Reader Net analyzer in North America - ThedaCare Medical Center-Wild Rose in Wisconsin is the first hospital in the U.S. and Canada to implement the DG Reader Net analyzer, helping automate pre-transfusion blood type matching and enhance patient sa...

Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year -- Prestigious healthcare research firm reaffirms PharmacyKeeper Verification as the No. 1 product for Intravenous (IV) Workflow Management -- PharmacyKeeper Verification is a strategic part of ...